Health Care • Hospital/Nursing Management
$181.52 ▼ -4.80
(-2.58%)
MKT CAP: $10.59B • VOL: 411.7K
52W L $142 52W H $218
ENSG // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $5.03B | $4.24B | $3.71B |
| YoY Revenue Growth % | +18.8% | +14.3% | — |
| Gross Profit | $1.01B | $860.6M | — |
| Gross Margin % | 20.1% | 20.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $425.3M | $358.3M | $255.4M |
| Operating Margin % | 8.5% | 8.5% | 6.9% |
| Net Income (GAAP) | $344.0M | $298.0M | $209.4M |
| EBITDA (Normalized) | $606.5M | $510.9M | $388.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $564.3M | $347.2M | $376.7M |
| Capital Expenditures (CapEx) | $226.4M | $190.7M | $166.9M |
| Free Cash Flow (FCF) | $337.8M | $156.5M | $209.8M |
| FCF Margin % | 6.7% | 3.7% | 5.7% |
| Return on Invested Capital (ROIC %) | 18.0% | 18.7% | 5.6% |
| Cash & Short-Term Equivalents | $503.9M | $464.6M | — |
| Total Debt (Short + Long Term) | $137.5M | $141.6M | $1.40B |
| Total Stockholders' Equity | $2.23B | $1.84B | $2.87B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ENSG.